SMAD4 Alterations are a Predictive Biomarker to Guide First-line Chemotherapy Selection for the Neoadjuvant Treatment of Localized Pancreatic Cancer : A Multicenter, Retrospective Cohort Study.

Overview of attention for article published in Annals of Surgery, October 2025

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (86th percentile)
Good Attention Score compared to outputs of the same age and source (74th percentile)

Mentioned by

news: 1 news outlet

twitter: 9 X users

Readers on

mendeley: 1 Mendeley

So far, Altmetric has seen 9 X posts from 9 X users, with an upper bound of 21,151 followers.

RT @Nedamini: SMAD4 Alterations are a Predictive Biomarker to Guide... : Annals of Surgery https://t.co/dSmSzQggo6

@JorgKleeff https://t.co/rDeuRqEUCV

Shoutout to authors - More data supporting SMAD4 loss mutation and PDAC resistance to FFX. Supports more investigation in alternative pathways activation / synthetic lethality and combinatorial strategies. ⁦@AnnalsofSurgery⁩ https://t.co/zK72RQlNkX

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 5 additional X posts.